Is a Housing Market Crash on the Way in 2021? | Midas Letter RAW ft GTBP & VXTRF
The real estate market has been booming. Surges in property valuations, lack of supply, and backlogs of new home constructions outside of major cities have been the recent trend. However, as Sir Isaac Newton pontificated; what goes up must come down. We never thought it would happen before, so could it happen again? Are we heading for another housing market crash?
The mortgage forbearance period has been extended and new protections will run through September 2021. These measures will only delay the pain people may suffer. Those who have been ravaged of financial resources due to the pandemic and were unable to pay their mortgages are still at risk. The end of the mortgage forbearance will likely cause a crisis when all deferred mortgage payments are demanded all at once. It has been estimated that over 200,000 defaults will occur this year and there will be over a 70% increase in foreclosures before 2023.
We saw that Wells Fargo told customers it’s shutting down all existing personal lines of credit in the coming weeks and no longer offer them as products. Is there more to read between the lines of that story?
While it’s impossible to predict the exact future of the real estate sector, it is probable that price growth will slow and we will see a market dip. But, a crash that needs a Brad Pitt, Christian Bale, Ryan Gosling, and Steve Carell movie made about it, not likely.
Still, it’s important to stay informed of market trends, consumer sentiments, and expert insights. This is why we have Voxtur Analytics back on the show this week.
Voxtur Analytics Corp (OTCMKTS:VXTRF, CVE:VXTR) is a transformational real estate technology company that is redefining industry standards. The company offers targeted data analytics to simplify tax solutions, property valuation and settlement services throughout the lending lifecycle for investors, lenders, government agencies and servicers. Voxtur’s platform makes valuing properties, receiving loans, and evaluating tax quicker, cheaper, and more accurate. The executive chairman joins us to discuss Voxtur’s recent milestones. Perhaps the most telling being the company’s blowout Q1 2021 quarter achieving a 183% increase in revenues.
We are not forgetting about the biotech market. No, not psychedelics this week but a company developing therapies for leukemia, among other cancers. GT Biopharma, Inc’s (NASDAQ:GTBP) TriKE™ platform enhances cancer killing abilities of a patient’s immune system natural killer cells (NK cells). Currently, the company has 40 different cancer therapies in its clinical study pipeline. In its most recent trial results, 57% of patients experienced a significant reduction in AML/MDS cancer cell burden and up to 63.7% reduction in bone marrow blast levels. This is an early sign that what GT Biopharma is doing is working and the company can therefore expand its efficacy studies.
Transcript
00:38 – Top dog Thelma Red Heeler
02:20 – Show Rundown
04:42 – Wells Fargo shutting down lines of credit
05:55 – Mortgage forbearance ending
07:05 – Another housing market collapse?
08:53 – Biotech market & GT Biopharma intro
10:47 – **GT Biopharma Inc (NASDAQ:GTBP) CEO Anthony Cataldo interview**
21:16 – GTBP chart
21:57 – **Voxtur Analytics Corp Exec Chairman Gary Yeoman interview**
Related Articles
Disclosure
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.
